Trials / Conditions / Stage IV Lip and Oral Cavity Cancer AJCC v8

Stage IV Lip and Oral Cavity Cancer AJCC v8

13 registered clinical trials studyying Stage IV Lip and Oral Cavity Cancer AJCC v8 — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Nec NCT06868433	Emory University	Phase 1
Recruiting	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni NCT06589804	National Cancer Institute (NCI)	Phase 3
Recruiting	Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058	Emory University	N/A
Recruiting	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, NCT06636734	Emory University	Phase 2
Withdrawn	Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845	ECOG-ACRIN Cancer Research Group	Phase 2
Active Not Recruiting	Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the NCT05721755	ECOG-ACRIN Cancer Research Group	Phase 3
Active Not Recruiting	Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy NCT05063552	National Cancer Institute (NCI)	Phase 2 / Phase 3
Recruiting	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Mel NCT05136196	National Cancer Institute (NCI)	Phase 2
Withdrawn	A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Canc NCT05512767	Mayo Clinic	N/A
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650	Marcelo Bonomi	Phase 2
Completed	Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With NCT04541355	Hyunseok Kang, MD	Phase 2